3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 3
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
19
Neutropenia
13
Hodgkin Disease
5
Lymphoma
4
Lymphoma, Large B-Cell, Diffuse
3
Chemotherapy-induced Neutropenia
3
Triple Negative Breast Neoplasms
2
Febrile Neutropenia
2
Dendritic Cell Sarcoma, Interdigitating
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms, Male
2
Sarcoma, Synovial
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrent Uterine Corpus Carcinoma
1
Rectal Neoplasms
1
Neurofibrosarcoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Heart Failure
1
Fibrosarcoma
1
Fever
1
Endometrial Adenocarcinoma
1
Interventions
Leucovorin
22
Fluorouracil
22
Gemcitabine
21
Capecitabine
21
Paclitaxel
20
Docetaxel
20
Irinotecan
15
Carboplatin
15
Radiosurgery
14
Oxaliplatin
13
Cisplatin
13
Bevacizumab
13
Zoledronic Acid
12
pembrolizumab
11
Radiotherapy
11
Fulvestrant
11
palbociclib
9
Pemetrexed
9
Drug Therapy
9
130-nm albumin-bound paclitaxel
9
Surgical Procedures, Operative
7
Letrozole
7
Ibandronic Acid
7
abemaciclib
6
Trastuzumab
6
Prednisone
6
Vinorelbine
5
Folfox protocol
5
Floxuridine
5
Doxorubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasm Metastasis
×
pegfilgrastim
×
Clear all
NCT01933932
2025-11-19
SELECT-1
AstraZeneca
Phase 3
Active not recruiting
510 enrolled
16 charts